Jubilant Pharmova Limited (JUBLPHARMA) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Jubilant Pharmova Limited stock ₹308, price ₹960, that is 67.9% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Jubilant Pharmova Limited
JUBLPHARMA · NSEFar too expensive (fair value 68% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range ₹264.40 – ₹1,257 · fair‑value band ₹308.33 – ₹319.00 · the ₹960.25 price screens above the ₹308.33 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether Jubilant Pharmova is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally.
Show moreShow less
It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs.
The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others.
Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products.
The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules.
Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty.
The Contract Research Development and Manufacturing Organisation segment offers drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases.
The company serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors.
The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.
Stock analysis
Jubilant Pharmova Limited (JUBLPHARMA) currently trades at ₹960.25, while our model-based Fair Value estimate is ₹308.33, 68% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹642.41 per share, and 1 of the 16 models we run sit above the ₹960.25 price.
Bear case: the Dividend Discount group reads lowest at ₹68.44, and 15 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹308.33 (bear) to ₹319.00 (bull), the price of ₹960.25 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Jubilant Pharmova Limited reported revenue of ₹82.8B in FY2026 versus ₹61.3B in FY2022, a compound +7.8%/yr. Reported net income was ₹4.0B in FY2026, compounding −0.9%/yr from FY2022.
Key figures
Market cap ₹153B (≈ $1.6B) Small · P/E ratio 43.3 · P/S ratio 1.77 · EPS (TTM) ₹22.17 · Dividend yield 0.5% · Net margin 4.1% · Return on equity 6.0% · Return on assets (EBIT) 17.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (medium confidence).
What moves the price
The share trades about 17% below its 52-week high and 20% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −68%, JUBLPHARMA screens richer than that median.
Fair Value models
All 16 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
JUBLPHARMA screens overvalued: fair value 68% below the price. Compare with Merck KGaA →
Compare Jubilant Pharmova Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EBIT margin by industry
- P/S ratio by industry
- Stock screener with 62 metrics
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs JUBLPHARMA |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs JUBLPHARMA |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs JUBLPHARMA |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs JUBLPHARMA |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs JUBLPHARMA |
| Galderma Group GALD | CHF 191.00 | CHF 112.30 | −41% | vs JUBLPHARMA |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs JUBLPHARMA |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs JUBLPHARMA |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs JUBLPHARMA |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs JUBLPHARMA |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Jubilant Pharmova Limited (JUBLPHARMA) overvalued or undervalued?
What is the fair value of JUBLPHARMA?
What is the quality score of JUBLPHARMA?
What is the price target for Jubilant Pharmova Limited (JUBLPHARMA)?
What is the Jubilant Pharmova Limited stock forecast for 2026?
What is the revenue of Jubilant Pharmova Limited (JUBLPHARMA)?
Does Jubilant Pharmova Limited pay a dividend?
How much is the dividend of Jubilant Pharmova Limited (JUBLPHARMA) and when is the ex-dividend date?
What is the intrinsic value of Jubilant Pharmova Limited (JUBLPHARMA)?
Is Jubilant Pharmova Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of JUBLPHARMA?
How much is Jubilant Pharmova Limited worth?
What do the bullish and bearish scenarios say about JUBLPHARMA?
What is the P/E ratio of JUBLPHARMA?
What is the PEG ratio of JUBLPHARMA?
How solid is the balance sheet of Jubilant Pharmova Limited (JUBLPHARMA)?
How far is JUBLPHARMA from its 52-week high?
Which stocks are comparable to Jubilant Pharmova Limited?
Is Jubilant Pharmova Limited stock attractive at the current price?
How is the fair value of JUBLPHARMA calculated?
Is it still worth investing in stocks now?
What is the share price of Jubilant Pharmova Limited (JUBLPHARMA)?
What should I pay attention to with Jubilant Pharmova Limited right now?
Where does the earnings growth of Jubilant Pharmova Limited (JUBLPHARMA) come from?
Key figures of Jubilant Pharmova Limited
How large is the market capitalisation of Jubilant Pharmova Limited (JUBLPHARMA)?
What is the P/S ratio of Jubilant Pharmova Limited (JUBLPHARMA)?
What are the earnings per share of Jubilant Pharmova Limited (JUBLPHARMA)?
What is the dividend yield of Jubilant Pharmova Limited (JUBLPHARMA)?
What is the net margin of Jubilant Pharmova Limited (JUBLPHARMA)?
What is the return on equity of Jubilant Pharmova Limited (JUBLPHARMA)?
What is the EBIT return on assets of Jubilant Pharmova Limited (JUBLPHARMA)?
What is the operating margin of Jubilant Pharmova Limited (JUBLPHARMA)?
How fast is revenue growing at Jubilant Pharmova Limited (JUBLPHARMA)?
How fast are earnings growing at Jubilant Pharmova Limited (JUBLPHARMA)?
How much free cash flow does Jubilant Pharmova Limited (JUBLPHARMA) generate?
How much net debt does Jubilant Pharmova Limited (JUBLPHARMA) carry?
Watch Jubilant Pharmova Limited in the live analysis
One click puts Jubilant Pharmova Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.